Ananym urges Bio-Techne to consider selling itself

0 min read | Published on 15 Jun 2026, 07:34 PM |Updated on 15 Jun 2026, 07:34 PM

Reviewed by

Suketu GScanX News Team

Key Highlights

Activist investor Ananym has urged Bio-Techne to consider selling itself, as reported by Bloomberg News on June 15, 2026. The proposal aims to unlock shareholder value through strategic alternatives. Bio-Techne has not yet responded publicly.

*this image is generated using AI for illustrative purposes only.

Activist investor Ananym has urged Bio-Techne to consider selling itself, according to a report by Bloomberg News on June 15, 2026. The recommendation aims to unlock shareholder value by exploring strategic alternatives, including a potential sale.

The report highlights that Ananym believes a sale could be beneficial for Bio-Techne and its stakeholders. No specific buyers or deal terms were mentioned in the report.

Bio-Techne has not yet issued a public response to the activist investor's proposal. The company's next steps regarding the potential sale remain unclear.

The development underscores growing activist interest in Bio-Techne's strategic direction. Shareholders will be closely watching for any updates from the company's board.

How might Bio-Techne's board respond to Ananym's proposal, and what strategic alternatives could they consider?

Who are the potential buyers that could be interested in acquiring Bio-Techne?

What impact could this activist pressure have on Bio-Techne's stock price in the short term?

Piper Sandler initiates coverage on Bio-Techne with Neutral rating

0 min read | Published on 11 Jun 2026, 04:16 PM |Updated on 11 Jun 2026, 04:16 PM

Reviewed by

Radhika SScanX News Team

Add as a preferred
source on Google

Key Highlights

Piper Sandler analyst David Westenberg has initiated coverage on Bio-Techne with a Neutral rating and announced a price target of $65.

*this image is generated using AI for illustrative purposes only.

Piper Sandler analyst David Westenberg has initiated coverage on Bio-Techne with a Neutral rating and announced a price target of $65. This rating provides a benchmark for investors evaluating the stock's potential performance relative to the firm's projections.

The coverage initiation by Piper Sandler offers a new perspective on Bio-Techne's market position. The Neutral rating suggests that the stock is expected to perform in line with the broader market or industry averages over the specified period.